We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SILC:NASDAQSilicom Ltd Analysis

Data as of 2026-05-01 - not real-time

$38.75

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Silicom Ltd. (SILC) is trading at $38.75, tightly hugging its 52‑week high and the calculated resistance of $39.12. Technicals remain bullish – the 20‑day SMA (26.59) sits above both the 50‑day (22.51) and 200‑day (17.89) averages, and the MACD line (2.99) is above its signal (2.36) with a positive histogram. However, the RSI is soaring at 78.6, flagging an overbought condition, while 30‑day volatility spikes above 117% and beta (≈1.38) signals heightened market sensitivity. Fundamentally, the company is struggling: negative operating and net margins, a trailing EPS of –$2.01, and a forward PE of –37.6. The balance sheet is relatively solid with $48.1 M cash versus $6.3 M debt, yet cash‑flow generation remains negative.
The recent $3 M annual FPGA SmartNIC contract with a European partner provides a tangible growth catalyst and could help lift revenue (up 16.7% YoY) and improve margins over the next 12‑18 months. Nonetheless, the stock’s current valuation (price‑to‑sales 3.57, price‑to‑book 1.88) appears stretched given the earnings deficit and extreme short‑term technical risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • RSI in overbought territory (78.6) suggests near‑term price correction
  • Price is at resistance ($39.12) with limited upside without catalyst
  • Increasing volume but negative earnings heighten downside risk

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • New $3 M FPGA SmartNIC contract could drive revenue growth
  • Technical bullish alignment of SMAs and MACD supports upside
  • Strong cash position provides runway for operational improvements

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Fundamental profitability remains negative, limiting valuation upside
  • Technology sector exposure and high beta keep market risk elevated
  • Potential for turnaround hinges on execution of growth contracts

Key Metrics & Analysis

Financial Health

Revenue Growth16.70%
Profit Margin-18.54%
P/E Ratio-37.6
ROE-9.36%
ROA-5.07%
Debt/Equity5.34
P/B Ratio1.9
Op. Cash Flow$-2160000
Free Cash Flow$-626125
Industry P/E37.9

Technical Analysis

TrendBullish
RSI78.6
Support$21.03
Resistance$39.12
MA 20$26.59
MA 50$22.51
MA 200$17.89
MACDBullish
VolumeIncreasing
Fear & Greed Index90.91

Valuation

GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.38
Volatility117.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.